News | July 21, 2025
Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
Most recently he served as Chief Operating Officer at Bharat Serums and Vaccines
Insights are drawn from over 30K+ people across 300+ cities including all metro and tier-1 cities
Annual EBITDA margin expands by 170 basis points
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
The transaction is expected to be completed by May 15, 2025 or such other date as may be mutually agreed
The system is powered by advanced imaging innovations such as Amber-red Color Imaging, Triple Noise Reduction, and Extended Dynamic Range Image Processing
Over 1500 stakeholders representing food businesses, packaging industries, recycling associations, regulatory bodies, environmental organizations, consumer groups, farmer groups, government departments participated in the consultation
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
